Evidence map›Paper›PMID 41468427›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Circular RNA-based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer.

Yudong Lin, Ruyue Wang, Fan Li, Zeyi Lu, Wenqin Luo, Haohua Lu, Zhehao Xu, Chang Xu, Yi Lu, Ziwei Zhu and 7 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yudong Lin *Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.ORCID 0000-0002-9881-9561
Ruyue Wang *Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Fan Li *Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Zeyi LuDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Wenqin LuoDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Haohua LuDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Zhehao XuDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Chang XuHangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
Yi LuDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Ziwei ZhuDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Yang LiDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Xudong MaoDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Liqun XiaDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Xiaojing YuDepartment of Radiology, Sir Run Run Shaw hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Wenjing SuZhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University, Hangzhou 310058, China.ORCID 0000-0002-1775-9115
Lifeng DingDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Gonghui LiDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.ORCID 0000-0001-9845-7241

Funding

Joint construction project of Zhejiang Province and Ministry 2020388200MOST | National Natural Science Foundation of China (NSFC) 82173221MOST | National Natural Science Foundation of China (NSFC) 82372687MOST | National Natural Science Foundation of China (NSFC) 82472720The Joint Funds of the Zhejiang Provincial Natural Science Foundation of China LHDMZ23H160004The "Pioneer" and "Leading Goose" R&D Program of Zhejiang Province 2024C03045
6 · The paper itself

Abstract

Androgen receptor (AR) signaling is essential for prostate cancer (PCa) cell growth and remains a key therapeutic target in castration-resistant PCa (CRPC). While circular RNAs (circRNAs) are increasingly recognized as important regulatory molecules, their roles in AR signaling during PCa progression remain poorly understood. This study identified

Indexed as

Fatty AcidsProstatic Neoplasms, Castration-ResistantRNA, CircularAcetyl-CoA CarboxylaseAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeReceptors, AndrogenSignal TransductionXenograft Model Antitumor AssaysACACA protein, humanAcetyl-CoA CarboxylaseAR protein, humanFatty AcidsReceptors, AndrogenRNA, Circularacetyl-CoA carboxylase 1androgen receptorcastration-resistant prostate cancercircular RNAfatty acid synthesis

Identifiers

PMID41468427
PMCPMC12773704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.